Research
Hormonal
Obesity pharmacotherapies, specifically high-dose semaglutide and tirzepatide, are highly effective for long-term weight management (>10% loss at 6 months) but remain dramatically underprescribed due to clinician knowledge gaps, safety concerns, and insurance coverage limitations.
If you qualify for obesity pharmacotherapy, discuss semaglutide or tirzepatide with your provider. While highly effective (>10% weight loss), access is limited by insurance. Ask about coverage options, especially if you have cardiovascular risk, as recent policy changes may improve access.
GoodSupportsHIGH confidence
The 2 pharmacotherapies approved most recently by the US Food and Drug Administration (FDA) for long-term weight management are high-dose semaglutide and tirzepatide, which are both associated with an average weight loss of >10% at 6 months in clinical environments... However, obesity pharmacotherapies continue to be dramatically underprescribed.
Why this rating
Based on FDA approvals and clinical trial data cited.
Source
Implementation of Obesity Science Into Clinical Practice: A Scientific Statement From the American Heart Association
Deepika Laddu et al. · Circulation · 2024
DOI 10.1161/cir.0000000000001221
clinical_guidelineCited 31×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery is the most effective long-term treatment for severe obesity, significantly reducing risks of CVD, type 2 diabetes, and adverse pregnancy outcomes, yet access is inequitable due to socioeconomic and structural barriers.Strong
- Overreliance on BMI as the sole metric for obesity management hinders clinical implementation and confuses clinicians, leading to suboptimal care; waist circumference is a more useful tool for assessing health risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →